Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2020-09-17
Target enrollment:
Participant gender:
Summary
This Phase I/II study is designed to first identify doses of MLN9708 and bendamustine that
are associated with an acceptable adverse event profile when delivered together in 28-day
cycles. Additionally, the study aims to assess the efficacy of the combination in patients
with relapsed/refractory multiple myeloma. Responders (stable disease or more), will continue
to receive up to eight cycles total in the absence of further progressive disease.